Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study

There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n =...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European psychiatry 2018-08, Vol.52, p.22-28
Hauptverfasser: Castaldelli-Maia, João Mauricio, Loreto, Aline Rodrigues, Guimarães-Pereira, Bruna Beatriz Sales, Carvalho, Carlos Felipe Cavalcanti, Gil, Felipe, Frallonardo, Fernanda Piotto, Ismael, Flávia, Andrade, Arthur Guerra de, Ventriglio, Antonio, Richter, Kimber P., Bhugra, Dinesh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 28
container_issue
container_start_page 22
container_title European psychiatry
container_volume 52
creator Castaldelli-Maia, João Mauricio
Loreto, Aline Rodrigues
Guimarães-Pereira, Bruna Beatriz Sales
Carvalho, Carlos Felipe Cavalcanti
Gil, Felipe
Frallonardo, Fernanda Piotto
Ismael, Flávia
Andrade, Arthur Guerra de
Ventriglio, Antonio
Richter, Kimber P.
Bhugra, Dinesh
description There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment. Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion. The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.
doi_str_mv 10.1016/j.eurpsy.2018.02.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2021318857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092493381830066X</els_id><sourcerecordid>2021318857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhDarKSzYJthMnThdI1aj8SJVYAGvLsW-op0kcfJ1W8wY8Np6ZliUrX1nfuUf3HEIuOCs5482HXQlrXHBfCsZVyUTJmHxBNrxtVVFJJV-SDetEXXRVpc7IG8QdY7xlrHlNzkTXsI7JZkP-fJ_CvZ9_UQuIJvkw0xTBpAnmRMOabJgAqZlCRhYIywj00ac7amZ3HDJCD6wZj1-49pjMbIGuCNR5DNFBxCt6PdPQI8SHo0ems8lYPIY4ZlFa3f4teTWYEeHd03tOfn66-bH9Utx--_x1e31b2JqpVNR11VuwXAk7HG5oB9EJEJUxqu6scjmatq-d60C0nRSuVWaQYIRgopFSVNU5eX_au8TwewVMevJoYRzNDGFFnUFecaVkm9H6hNoYECMMeol-MnGvOdOHDvROnzrQhw40Ezp3kGWXTw5rP4H7J3oOPQMfTwDkOx88RI3WQw7N-Qg2aRf8_x3-AsQPnS4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2021318857</pqid></control><display><type>article</type><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</creator><creatorcontrib>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</creatorcontrib><description>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment. Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion. The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1016/j.eurpsy.2018.02.005</identifier><identifier>PMID: 29609056</identifier><language>eng</language><publisher>England: Elsevier Masson SAS</publisher><subject>Adult ; Brazil ; Bupropion - therapeutic use ; Cognitive Behavioral Therapy - methods ; Combined Modality Therapy ; Comorbidity ; Female ; Humans ; Male ; Mental Disorders - complications ; Mental Disorders - psychology ; Mental health ; Middle Aged ; Nicotine - therapeutic use ; Nortriptyline - therapeutic use ; Outcome and Process Assessment, Health Care ; Psychotherapy, Group - methods ; Smoking ; Smoking - psychology ; Smoking Cessation - psychology ; Substance use disorders ; Substance-Related Disorders - complications ; Substance-Related Disorders - psychology ; Tobacco ; Treatment ; Treatment Outcome</subject><ispartof>European psychiatry, 2018-08, Vol.52, p.22-28</ispartof><rights>2018 Elsevier Masson SAS</rights><rights>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</citedby><cites>FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</cites><orcidid>0000-0001-9621-2291</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29609056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castaldelli-Maia, João Mauricio</creatorcontrib><creatorcontrib>Loreto, Aline Rodrigues</creatorcontrib><creatorcontrib>Guimarães-Pereira, Bruna Beatriz Sales</creatorcontrib><creatorcontrib>Carvalho, Carlos Felipe Cavalcanti</creatorcontrib><creatorcontrib>Gil, Felipe</creatorcontrib><creatorcontrib>Frallonardo, Fernanda Piotto</creatorcontrib><creatorcontrib>Ismael, Flávia</creatorcontrib><creatorcontrib>Andrade, Arthur Guerra de</creatorcontrib><creatorcontrib>Ventriglio, Antonio</creatorcontrib><creatorcontrib>Richter, Kimber P.</creatorcontrib><creatorcontrib>Bhugra, Dinesh</creatorcontrib><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><title>European psychiatry</title><addtitle>Eur Psychiatry</addtitle><description>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment. Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion. The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</description><subject>Adult</subject><subject>Brazil</subject><subject>Bupropion - therapeutic use</subject><subject>Cognitive Behavioral Therapy - methods</subject><subject>Combined Modality Therapy</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Mental Disorders - complications</subject><subject>Mental Disorders - psychology</subject><subject>Mental health</subject><subject>Middle Aged</subject><subject>Nicotine - therapeutic use</subject><subject>Nortriptyline - therapeutic use</subject><subject>Outcome and Process Assessment, Health Care</subject><subject>Psychotherapy, Group - methods</subject><subject>Smoking</subject><subject>Smoking - psychology</subject><subject>Smoking Cessation - psychology</subject><subject>Substance use disorders</subject><subject>Substance-Related Disorders - complications</subject><subject>Substance-Related Disorders - psychology</subject><subject>Tobacco</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhS0EokPhDarKSzYJthMnThdI1aj8SJVYAGvLsW-op0kcfJ1W8wY8Np6ZliUrX1nfuUf3HEIuOCs5482HXQlrXHBfCsZVyUTJmHxBNrxtVVFJJV-SDetEXXRVpc7IG8QdY7xlrHlNzkTXsI7JZkP-fJ_CvZ9_UQuIJvkw0xTBpAnmRMOabJgAqZlCRhYIywj00ac7amZ3HDJCD6wZj1-49pjMbIGuCNR5DNFBxCt6PdPQI8SHo0ems8lYPIY4ZlFa3f4teTWYEeHd03tOfn66-bH9Utx--_x1e31b2JqpVNR11VuwXAk7HG5oB9EJEJUxqu6scjmatq-d60C0nRSuVWaQYIRgopFSVNU5eX_au8TwewVMevJoYRzNDGFFnUFecaVkm9H6hNoYECMMeol-MnGvOdOHDvROnzrQhw40Ezp3kGWXTw5rP4H7J3oOPQMfTwDkOx88RI3WQw7N-Qg2aRf8_x3-AsQPnS4</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Castaldelli-Maia, João Mauricio</creator><creator>Loreto, Aline Rodrigues</creator><creator>Guimarães-Pereira, Bruna Beatriz Sales</creator><creator>Carvalho, Carlos Felipe Cavalcanti</creator><creator>Gil, Felipe</creator><creator>Frallonardo, Fernanda Piotto</creator><creator>Ismael, Flávia</creator><creator>Andrade, Arthur Guerra de</creator><creator>Ventriglio, Antonio</creator><creator>Richter, Kimber P.</creator><creator>Bhugra, Dinesh</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9621-2291</orcidid></search><sort><creationdate>201808</creationdate><title>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</title><author>Castaldelli-Maia, João Mauricio ; Loreto, Aline Rodrigues ; Guimarães-Pereira, Bruna Beatriz Sales ; Carvalho, Carlos Felipe Cavalcanti ; Gil, Felipe ; Frallonardo, Fernanda Piotto ; Ismael, Flávia ; Andrade, Arthur Guerra de ; Ventriglio, Antonio ; Richter, Kimber P. ; Bhugra, Dinesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-443bcec182cf60907f292e23aa849c8d1017b4dd9e27952d78af5ea2202655233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Brazil</topic><topic>Bupropion - therapeutic use</topic><topic>Cognitive Behavioral Therapy - methods</topic><topic>Combined Modality Therapy</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Mental Disorders - complications</topic><topic>Mental Disorders - psychology</topic><topic>Mental health</topic><topic>Middle Aged</topic><topic>Nicotine - therapeutic use</topic><topic>Nortriptyline - therapeutic use</topic><topic>Outcome and Process Assessment, Health Care</topic><topic>Psychotherapy, Group - methods</topic><topic>Smoking</topic><topic>Smoking - psychology</topic><topic>Smoking Cessation - psychology</topic><topic>Substance use disorders</topic><topic>Substance-Related Disorders - complications</topic><topic>Substance-Related Disorders - psychology</topic><topic>Tobacco</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castaldelli-Maia, João Mauricio</creatorcontrib><creatorcontrib>Loreto, Aline Rodrigues</creatorcontrib><creatorcontrib>Guimarães-Pereira, Bruna Beatriz Sales</creatorcontrib><creatorcontrib>Carvalho, Carlos Felipe Cavalcanti</creatorcontrib><creatorcontrib>Gil, Felipe</creatorcontrib><creatorcontrib>Frallonardo, Fernanda Piotto</creatorcontrib><creatorcontrib>Ismael, Flávia</creatorcontrib><creatorcontrib>Andrade, Arthur Guerra de</creatorcontrib><creatorcontrib>Ventriglio, Antonio</creatorcontrib><creatorcontrib>Richter, Kimber P.</creatorcontrib><creatorcontrib>Bhugra, Dinesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castaldelli-Maia, João Mauricio</au><au>Loreto, Aline Rodrigues</au><au>Guimarães-Pereira, Bruna Beatriz Sales</au><au>Carvalho, Carlos Felipe Cavalcanti</au><au>Gil, Felipe</au><au>Frallonardo, Fernanda Piotto</au><au>Ismael, Flávia</au><au>Andrade, Arthur Guerra de</au><au>Ventriglio, Antonio</au><au>Richter, Kimber P.</au><au>Bhugra, Dinesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study</atitle><jtitle>European psychiatry</jtitle><addtitle>Eur Psychiatry</addtitle><date>2018-08</date><risdate>2018</risdate><volume>52</volume><spage>22</spage><epage>28</epage><pages>22-28</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>There is a lack of studies evaluating smoking cessation treatment protocols which include people with and without mental and substance use disorders (MSUD), and which allows for individuals with MSUD undergoing their psychiatric treatment. We compared treatment success between participants with (n = 277) and without (n = 419) MSUD among patients in a 6-week treatment provided by a Brazilian Psychosocial Care Center (CAPS) from 2007 to 2013. Sociodemographic, medical and tobacco use characteristics were assessed at baseline. Tobacco treatment consisted of 1) group cognitive behavior therapy, which included people with and without MSUD in the same groups, and 2) pharmacotherapy, which could include either nicotine patches, nicotine gum, bupropion or nortriptyline. For participants with MSUD, tobacco treatment was integrated into their ongoing mental health treatment. The main outcome was 30-day point prevalence abstinence, measured at last day of treatment. Abstinence rates did not differ significantly between participants with and without MSUD (31.1% and 34.4%, respectively). Variables that were significantly associated with treatment success included years smoking, the Heaviness of Smoking Index, and use of nicotine patch or bupropion. The inclusion of individuals with and without MSUD in the same protocol, allowing for individuals with MSUD undergoing their psychiatric treatment, generates at least comparable success rates between the groups. Predictors of treatment success were similar to those found in the general population. Facilities that treat patients with MSUD should treat tobacco use in order to reduce the disparities in morbidity and mortality experienced by this population.</abstract><cop>England</cop><pub>Elsevier Masson SAS</pub><pmid>29609056</pmid><doi>10.1016/j.eurpsy.2018.02.005</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9621-2291</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0924-9338
ispartof European psychiatry, 2018-08, Vol.52, p.22-28
issn 0924-9338
1778-3585
language eng
recordid cdi_proquest_miscellaneous_2021318857
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Brazil
Bupropion - therapeutic use
Cognitive Behavioral Therapy - methods
Combined Modality Therapy
Comorbidity
Female
Humans
Male
Mental Disorders - complications
Mental Disorders - psychology
Mental health
Middle Aged
Nicotine - therapeutic use
Nortriptyline - therapeutic use
Outcome and Process Assessment, Health Care
Psychotherapy, Group - methods
Smoking
Smoking - psychology
Smoking Cessation - psychology
Substance use disorders
Substance-Related Disorders - complications
Substance-Related Disorders - psychology
Tobacco
Treatment
Treatment Outcome
title Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A11%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Smoking%20cessation%20treatment%20outcomes%20among%20people%20with%20and%20without%20mental%20and%20substance%20use%20disorders:%20An%20observational%20real-world%20study&rft.jtitle=European%20psychiatry&rft.au=Castaldelli-Maia,%20Jo%C3%A3o%20Mauricio&rft.date=2018-08&rft.volume=52&rft.spage=22&rft.epage=28&rft.pages=22-28&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1016/j.eurpsy.2018.02.005&rft_dat=%3Cproquest_cross%3E2021318857%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2021318857&rft_id=info:pmid/29609056&rft_els_id=S092493381830066X&rfr_iscdi=true